Bernardes-Silva Carlos Felipe, Pereira Alexandre C, de Fátima Alves da Mota Glória, Krieger José Eduardo, Laudanna Antonio Atílio
Department of Gastroenterology - University of São Paulo School of Medicine, São Paulo, SP, Brazil.
Clin Chim Acta. 2007 Nov-Dec;386(1-2):7-11. doi: 10.1016/j.cca.2007.07.012. Epub 2007 Jul 19.
Irritable bowel syndrome (IBS) is a symptom-based disorder characterized by abdominal pain related to altered bowel habit. We evaluated the predictive power of 2 genetic markers of hypolactasia, C/T_13910 and G/A_22018, in IBS patients with and without lactose intolerance in order to gain insight into the role of lactose intolerance in IBS.
Seventy five patients (59F/16M, mean age: 49.6+/-14.2 years) with an IBS diagnosis based on Rome II criteria and 272 healthy individuals, where 74 (58F/16M, 54.1+/-10.9 years) were matched-controls, were evaluated. IBS and healthy individuals were genotyped for the C/T_13910 and G/A_22018 polymorphisms nearby the lactase-phlorizin hydrolase gene. Hydrogen breath test (HBT) with gas chromatography was performed in IBS patients to assess for lactose intolerance.
Of the 75 IBS patients, 28 (37%) were defined as lactose intolerants. The grade/severity of symptoms after an oral lactose load were positively correlated to the expiratory H2 excretion (P<0.001). Alleles and genotypes frequencies from C/T_13910 and G/A_22018 were not significantly different between IBS patients and control individuals (P>0.05;NS). Presence of the C and G allele were positively associated with a higher expiratory hydrogen excretion and more intense gastrointestinal symptoms (P<0.001). Considering these polymorphisms as a diagnostic test for lactose intolerance in IBS patients, presence of the CC and GG genotypes were estimated to have, a sensitivity of 100% and 96%, respectively; and a specificity of 83% and 79%, positive predictive value of 76% and 73%, and negative predictive value of 100% and 97%.
In IBS patients, genotyping of C/T_13910 and G/A_22018 polymorphisms predicts gastrointestinal symptoms after lactose ingestion and are a diagnostic tool for lactose intolerance.
肠易激综合征(IBS)是一种基于症状的疾病,其特征为与排便习惯改变相关的腹痛。我们评估了低乳糖血症的两个基因标记C/T_13910和G/A_22018在有或无乳糖不耐受的IBS患者中的预测能力,以便深入了解乳糖不耐受在IBS中的作用。
对75例根据罗马II标准诊断为IBS的患者(59名女性/16名男性,平均年龄:49.6±14.2岁)和272名健康个体进行评估,其中74名(58名女性/16名男性,54.1±10.9岁)为匹配对照。对IBS患者和健康个体进行乳糖酶-根皮苷水解酶基因附近的C/T_13910和G/A_22018多态性基因分型。对IBS患者进行气相色谱法氢呼气试验(HBT)以评估乳糖不耐受情况。
75例IBS患者中,28例(37%)被定义为乳糖不耐受。口服乳糖负荷后症状的分级/严重程度与呼气氢气排泄呈正相关(P<0.001)。IBS患者和对照个体之间C/T_13910和G/A_22018的等位基因和基因型频率无显著差异(P>0.05;无统计学意义)。C和G等位基因的存在与较高的呼气氢气排泄和更严重的胃肠道症状呈正相关(P<0.001)。将这些多态性作为IBS患者乳糖不耐受的诊断测试,CC和GG基因型的存在估计分别具有100%和96%的敏感性;83%和79%的特异性,76%和73%的阳性预测值,以及100%和97%的阴性预测值。
在IBS患者中,C/T_13910和G/A_22018多态性基因分型可预测乳糖摄入后的胃肠道症状,是乳糖不耐受的一种诊断工具。